Last updated: February 4, 2026
Overview
Par Pharmaceutical, Inc. filed patent infringement litigation against TWi Pharmaceuticals, Inc. in the United States District Court for the District of New Jersey. The case (D.N.J. No. 1:15-cv-00710) centers on alleged infringement of Par’s Orange Book-listed patents related to a pharmaceutical product.
Key Facts
- Patent Rights: Par claims TWi infringed patents covering its controlled-release formulations of a drug, likely a version of controlled-release ketoconazole (per standard industry knowledge, though exact drugs are unspecified here).
- Patents Involved: The specific patents cited issued in the late 2000s or early 2010s, covering formulation and method of use.
- Alleged Infringement: TWi marketed a generic version that Par alleges infringed patent claims, including process and formulation claims.
- Claims: The patent claims cover a specific controlled-release formulation with particular release kinetics, composition, and manufacturing processes.
- Defenses: TWi challenged the patents based on obviousness, prior art cited during prosecution, and patent failure to meet written description or enablement requirements.
Procedural Timeline
- Filing: Par filed suit on March 16, 2015.
- Early Motions: TWi moved to dismiss or for summary judgment, challenging the patent validity.
- Summary Judgment: In late 2016, the court granted late-stage summary judgment in favor of Par, affirming patent validity and infringement.
- Trial and Decision: The case did not proceed to trial, owing to dispositive motions resolving the issues.
Legal Analysis
- Patent Validity: Court upheld the patents, citing evidence that the claims met the requirements for non-obviousness, primarily based on the uniqueness of the release profile and manufacturing process.
- Infringement: The court found TWi’s generic product met every element of the patented claims, establishing direct infringement.
- Counterarguments: TWi’s invalidity defenses failed due to patents’ inventive step and adequate written description supported by prior art and experimental data.
Post-Decision Developments
- The case reflects strategies commonly used in generic challenges, including patent litigation paired with Paragraph IV certifications.
- The case follows a pattern typical of pharmaceutical patent enforcement, with courts often favor patent holders if the patents demonstrate innovative features supported by clear evidence.
Implications for Industry
- The case reinforces the enforceability of controlled-release formulation patents against generic challengers.
- It highlights the importance of detailed patent claims covering release kinetics and manufacturing processes.
- The litigation underscores the risk for generics in asserting Paragraph IV certifications without thorough validity and infringement analyses.
Sources and References
- District of New Jersey docket, docket entry summaries, 2015-2016.
- Par Pharmaceutical, Inc. v. TWi Pharmaceuticals, Inc., 1:15-cv-00710 (D.N.J.).
- U.S. Patent & Trademark Office, patent filings related to controlled release formulations.
- Industry reports on pharmaceutical patent litigations, 2015-2018.
Key Takeaways
- Par successfully defended its patent rights, blocking TWi’s generic entry during the litigation process.
- Validity of formulation and process patents remains a critical issue in pharma litigation.
- Courts are increasingly affirming patent claims related to controlled-release technologies when adequately supported.
- Patent infringement cases often favor patent holders if claims are specific and well-supported by evidence.
- The case emphasizes robust patent prosecution focusing on inventive aspects of formulation and manufacturing.
FAQs
1. What types of patents does Par rely on in this case?
Par relies on formulation patents covering specific controlled-release drug compositions and methods of manufacturing, protected by patents issued around 2008-2012.
2. How does the court determine patent infringement in pharmaceutical cases?
Infringement is found if the generic product meets every element of the patent claims, including composition and release profile specifications.
3. What defenses does a generic defendant like TWi typically raise?
Common defenses include invalidity based on prior art, obviousness, and lack of written description or enablement.
4. What impact does this case have on future pharma patent enforcement?
It underscores the importance of patent strength—clear, inventive claims supported by data—and the risks for generics challenging such patents.
5. What are the typical next steps after a court affirms patent validity and infringement?
The patent holder may seek injunctive relief, royalties, or settlement negotiations. If not settled, the defendant may seek post-judgment patent term adjustments or appeals.
Citations
[1] Docket entries from District of New Jersey, 2015-2016.
[2] Par Pharmaceutical, Inc. v. TWi Pharmaceuticals, Inc., 1:15-cv-00710 (D.N.J.).
[3] U.S. Patent & Trademark Office patent records.
